Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Large Increase in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 27,938 shares, an increase of 1,415.9% from the December 15th total of 1,843 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 84,214 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 84,214 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the company’s stock are sold short.

Guided Therapeutics Stock Down 16.2%

GTHP stock opened at $0.36 on Tuesday. The firm has a 50 day moving average of $0.31 and a two-hundred day moving average of $0.27. Guided Therapeutics has a 12 month low of $0.06 and a 12 month high of $0.54. The company has a market capitalization of $31.40 million, a price-to-earnings ratio of -7.29 and a beta of 0.49.

Guided Therapeutics (OTCMKTS:GTHP) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.